Gencurix Inc. (KOSDAQ:229000)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,536.00
+26.00 (1.72%)
At close: Dec 5, 2025
-6.00%
Market Cap 24.76B
Revenue (ttm) 3.39B
Net Income (ttm) -12.55B
Shares Out 16.12M
EPS (ttm) -877.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,466
Average Volume 504,201
Open 1,510.00
Previous Close 1,510.00
Day's Range 1,502.00 - 1,600.00
52-Week Range 1,131.00 - 2,635.00
Beta 0.62
RSI 49.22
Earnings Date Aug 11, 2025

About Gencurix

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was fo... [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 2011
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 229000
Full Company Profile

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.

Financial Statements

News